Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca and Evotec agree kidney disease alliance

AstraZeneca and Evotec agree kidney disease alliance

23rd October 2013

AstraZeneca has announced a new collaboration with Evotec focusing on the creation of new kidney disease therapies.

The alliance will initially involve exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease, taking advantage of Evotec's drug discovery platform capabilities.

AstraZeneca will receive access to a selected series of molecules identified in a screening effort, with this particular programme having been designed to explore a key kidney disease mechanism.

Evotec will receive funding support from its partner and contribute its expertise in this field, while AstraZeneca will provide industrial scope and scale, as well as its understanding of pharmaceutical development and marketing capabilities.

Dr Marcus Schindler, head of cardiovascular and metabolic diseases for AstraZeneca's iMed business, said: "Evotec has built a leading drug discovery platform in the field of kidney diseases and is well-positioned to work with us to generate highly innovative drug candidates."

This comes after the company announced that it has commenced a phase III trial programme for selumetinib, its new therapy for metastatic non-small-cell lung cancer, earlier this week.ADNFCR-8000103-ID-801652446-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.